Breast cancer
Study of Immunotherapy in Triple negative breast cancer after surgery
Who can joinAsk the trial team
AgeAsk the trial team
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Last updated on the registry 15 Sep 2025. Please confirm with the hospital that this trial is still taking patients.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Dr. B. R. Ambedkar, Institute Rotary Cancer HospitalNew Delhi, DelhiDirections ↗
Registry summary (technical)
Addition of low-dose pembrolizumab to capecitabine for residual triple negative breast cancer post neoadjuvant chemotherapy: An investigator-initiated multicentric open-labelled phase III randomized controlled clinical trial - SCRIPT Trial
Sponsor: Indian Council of Medical Research
CTRI/2024/02/062710 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 15 Sep 2025 · read by us 5 Nov 2026